Kurs & Likviditet
|Lista||Small Cap Stockholm|
|2019-08-01||Extra Bolagsstämma 2019|
|2019-05-23||Ordinarie utdelning NUE 0.00 SEK|
|2018-05-29||Ordinarie utdelning NUE 0.00 SEK|
|2017-10-13||Ordinarie utdelning NUE 0.00 SEK|
|2016-09-07||Ordinarie utdelning NUE 0.00 SEK|
|2016-07-01||Extra Bolagsstämma 2016|
The recommended public cash offer by Amgen Inc. ("Amgen") to the shareholders of Nuevolution AB (publ) ("Nuevolution") to tender all their shares in Nuevolution to Amgen (the "Offer") was declared unconditional and was completed by Amgen on 8 July 2019. As announced by Amgen, shares and warrants corresponding in aggregate to approximately 97.8% of the total number of shares and votes in Nuevolution (on a fully diluted basis) have been tendered to Amgen in the Offer and in the separate offer to the holders of warrants issued by Nuevolution. Amgen announced that it intends to request the initiation of mandatory acquisition proceedings in respect of the remaining shares in Nuevolution. When the offer was declared unconditional, it was also communicated that the acceptance period was extended up to and including 24 July 2019, 17:00 CEST, to allow remaining shareholders in Nuevolution to accept the Offer.
At the request of Amgen, the board of directors of Nuevolution has resolved to apply for delisting of Nuevolution's shares from Nasdaq Stockholm. The last day of trading in Nuevolution's shares on Nasdaq Stockholm will be announced as soon as Nuevolution has received confirmation of such date from Nasdaq Stockholm.
For more information, please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 7020 0987
Johnny Stilou, CFO
Phone: +45 8877 5973
Information about Nuevolution AB (publ)
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution's internal programs are focused on therapeutically important diseases targets within severe inflammatory diseases and cancer.
This information was released for publication at 18.00 CEST on 11 July 2019.
Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com.